全文获取类型
收费全文 | 2539415篇 |
免费 | 183864篇 |
国内免费 | 3866篇 |
专业分类
耳鼻咽喉 | 35489篇 |
儿科学 | 82979篇 |
妇产科学 | 68327篇 |
基础医学 | 374094篇 |
口腔科学 | 69815篇 |
临床医学 | 225581篇 |
内科学 | 493556篇 |
皮肤病学 | 58165篇 |
神经病学 | 202418篇 |
特种医学 | 96542篇 |
外国民族医学 | 538篇 |
外科学 | 383812篇 |
综合类 | 48773篇 |
现状与发展 | 12篇 |
一般理论 | 900篇 |
预防医学 | 194961篇 |
眼科学 | 59111篇 |
药学 | 189248篇 |
9篇 | |
中国医学 | 4941篇 |
肿瘤学 | 137874篇 |
出版年
2021年 | 20040篇 |
2019年 | 22687篇 |
2018年 | 31662篇 |
2017年 | 23761篇 |
2016年 | 26911篇 |
2015年 | 30162篇 |
2014年 | 41624篇 |
2013年 | 61692篇 |
2012年 | 86373篇 |
2011年 | 90898篇 |
2010年 | 53790篇 |
2009年 | 50412篇 |
2008年 | 84953篇 |
2007年 | 90616篇 |
2006年 | 91386篇 |
2005年 | 89207篇 |
2004年 | 85093篇 |
2003年 | 82000篇 |
2002年 | 79252篇 |
2001年 | 113907篇 |
2000年 | 116502篇 |
1999年 | 97657篇 |
1998年 | 27076篇 |
1997年 | 23363篇 |
1996年 | 23456篇 |
1995年 | 23543篇 |
1994年 | 21633篇 |
1993年 | 20414篇 |
1992年 | 74226篇 |
1991年 | 72429篇 |
1990年 | 70659篇 |
1989年 | 67827篇 |
1988年 | 62198篇 |
1987年 | 61036篇 |
1986年 | 57005篇 |
1985年 | 54713篇 |
1984年 | 40618篇 |
1983年 | 34482篇 |
1982年 | 20577篇 |
1979年 | 37224篇 |
1978年 | 26631篇 |
1977年 | 22064篇 |
1976年 | 21074篇 |
1975年 | 22905篇 |
1974年 | 27321篇 |
1973年 | 25964篇 |
1972年 | 24324篇 |
1971年 | 23103篇 |
1970年 | 21253篇 |
1969年 | 20236篇 |
排序方式: 共有10000条查询结果,搜索用时 192 毫秒
21.
22.
23.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
24.
Ali Soroush Reza Malekzadeh Gholamreza Roshandel Masoud Khoshnia Hossein Poustchi Farin Kamangar Paul Brennan Paolo Boffetta Sanford M. Dawsey Christian C. Abnet Julian A. Abrams Arash Etemadi 《International journal of cancer. Journal international du cancer》2023,152(6):1137-1149
Prior studies have conflicting findings regarding the association between gastroesophageal reflux disease (GERD) and esophageal squamous cell carcinoma (ESCC). We examined this relationship in a prospective cohort in a region of high ESCC incidence. Baseline exposure data were collected from 50 045 individuals using in-person interviews at the time of cohort entry. Participants were followed until they developed cancer, died, or were lost to follow up. Participants with GERD symptoms were categorized into any GERD (heartburn or regurgitation), mixed symptoms, or heartburn alone. Multivariable Cox regression was used to assess the relationship between GERD symptom group and histologically confirmed ESCC. The model was adjusted for known risk factors for GERD and ESCC. 49 559 individuals were included in this study, of which 9005 had GERD symptoms. Over 13.0 years of median follow up, 290 individuals were diagnosed with ESCC. We found no association between any GERD and risk of ESCC (aHR 0.90, 95% CI: 0.66-1.24, P = .54). Similar findings were observed for the GERD symptom subtypes. Significant interactions between any GERD and sex (P = .013) as well as tobacco smoking (P = .028) were observed. In post-hoc analyses, GERD was associated with a decreased risk of ESCC in men (aHR 0.51, 95% CI: 0.27-0.98 P = .04) and in smokers (aHR 0.26, 95% CI: 0.08-0.83 P = .02). While there was little evidence for an overall association between GERD symptoms and ESCC risk, significant interactions with sex and smoking were observed. Men and smokers with GERD symptoms had a lower risk of ESCC development. 相似文献
25.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
26.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
27.
Münch F. Purbojo A. Wenzel F. Kohl M. Dittrich S. Rauh M. Zimmermann R. Kwapil N. 《Der Anaesthesist》2022,71(11):882-892
Die Anaesthesiologie - Die Transfusion von Erythrozytenkonzentraten (EK) ist mit verschiedenen Nebenwirkungen assoziiert, die u. a. durch Lagerungsschäden an Erythrozyten hervorgerufen... 相似文献
28.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
29.
Georgios D. Lianos MD PhD Maximos Frountzas MD MPA PhD Dimitrios Schizas MD PhD Evangelos G. Baltagiannis MD George A. Alexiou MD PhD Christina Bali MD PhD Georgios K. Glantzounis MD PhD Michail Mitsis MD PhD Konstantinos Vlachos MD PhD 《Journal of surgical oncology》2023,127(1):7-10
During first outburst of COVID-19, several strategies had been applied for surgical oncology patients to minimize COVID-19 transmission. COVID-19 infection seemed to compromise survival and major complication rates of surgical oncology patients. However, survival, tumor progression and recurrence rates of surgical oncology patients were associated to the consequences of COVID-19 pandemic on their management. In addition, the severity of COVID-19 infections has been downgraded. Therefore, management of surgical oncology patients should be reconsidered. 相似文献